---
title: "Otezla (apremilast), all indications: Pharmacology questions"
description: "Pharmacology questions on Otezla (apremilast) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Otezla work (mechanism of action)? How is Otezla metabolized and eliminated? How long does Otezla stay in your system (half-life)? What are the inactive ingredients in Otezla and Otezla XR tablets? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/otezla/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast), all indications: Pharmacology questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)

## Mechanism

<a id="otezla-mechanism"></a>

### How does Otezla work (mechanism of action)?

> “Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic 
> adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The 
> specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

> “In clinical studies, apremilast decreased IL-17, IL-22 and TNF-alpha levels circulating in blood and 
> reduced expression of these pro-inflammatory cytokine genes in skin. The clinical implications of these 
> pharmacodynamic responses remain unclear.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

> “PDE4 is a cAMP-specific PDE that has been shown to degrade cAMP to AMP in inflammatory cells <sup>3,7</sup>”

Source: [OTEZLA: Mechanism of Action (MOA), captured 2026-11-13](https://www.otezlapro.com/how-otezla-works/#:~:text=PDE4%20is%20a%20cAMP%2Dspecific%20PDE,to%20AMP%20in%20inflammatory%20cells)

## Pharmacokinetics

<a id="otezla-metabolism"></a>

### How is Otezla metabolized and eliminated?

> “Following oral administration in humans, apremilast is a major circulating component (45%) followed by 
> inactive metabolite M12 (39%), a glucuronide conjugate of O-demethylated apremilast. It is extensively 
> metabolized in humans with up to 23 metabolites identified in plasma, urine and feces. Apremilast is 
> metabolized by both cytochrome (CYP) oxidative metabolism with subsequent glucuronidation and 
> non-CYP mediated hydrolysis. In vitro, CYP metabolism of apremilast is primarily mediated by 
> CYP3A4, with minor contributions from CYP1A2 and CYP2A6.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

> “Following oral administration of radiolabeled apremilast, about 58% 
> and 39% of the radioactivity is recovered in urine and feces, respectively, with about 3% and 7% of the 
> radioactive dose recovered as apremilast in urine and feces, respectively.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

<a id="otezla-half-life"></a>

### How long does Otezla stay in your system (half-life)?

> “The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal elimination 
> half-life of approximately 6-9 hours.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

> “OTEZLA when taken orally is absorbed with an absolute bioavailability of ~73%, with peak plasma 
> concentrations (Cmax) occurring at a median time (tmax) of ~2.5 hours.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

> “OTEZLA XR when taken orally is absorbed with peak plasma concentrations (Cmax) occurring at a 
> median time (tmax) of ~6 hours.”

Source: [OTEZLA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=17)

## Components

<a id="otezla-inactive-ingredients"></a>

### What are the inactive ingredients in Otezla and Otezla XR tablets?

> “OTEZLA (apremilast) tablets are supplied in 10 mg, 20 mg, and 30 mg strengths for oral administration. 
> Each tablet contains apremilast as the active ingredient and the following inactive ingredients: 
> croscarmellose sodium, iron oxide red, iron oxide yellow (20 and 30 mg only), iron oxide black (30 mg 
> only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, 
> polyvinyl alcohol, talc, titanium dioxide.”

Source: [OTEZLA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=16)

> “OTEZLA XR (apremilast) extended-release tablets are supplied in a 75 mg strength for oral 
> administration. Each tablet contains apremilast as the active ingredient and the following inactive 
> ingredients: cellulose acetate, colloidal silicon dioxide, ferrosoferric oxide, hydroxypropyl 
> methylcellulose acetate succinate, hypromellose, iron oxide red, magnesium stearate, mannitol, 
> microcrystalline cellulose, polyethylene glycol, polyethylene oxide, sodium chloride, titanium dioxide.”

Source: [OTEZLA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=16)

## Related pages
- [Medical information: Otezla (apremilast): All indications](https://www.evicenter.com/medical-information/otezla)
- [Indication](https://www.evicenter.com/medical-information/otezla/indication)
- [Safety](https://www.evicenter.com/medical-information/otezla/safety)
- [Specific populations](https://www.evicenter.com/medical-information/otezla/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/otezla/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/otezla/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/otezla/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/otezla/access-and-coverage)
